Belite Bio
BLTE
6 hedge funds and large institutions have $2.15M invested in Belite Bio in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.29% more ownership
Funds ownership: 0% → 0.29% (+0.29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWS
Atria Wealth Solutions
New York
|
+$927K |
| 2 |
Millennium Management
New York
|
+$169K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$124K |
| 4 |
BAMF
BI Asset Management Fondsmaeglerselskab
Kobenhavn,
Denmark
|
+$55.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$12.8K |
Top Sellers
BLTE Hedge Fund Activity: Q2 2022 in Review
6 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q2 2022, worth a combined $2.15M.
Buyers outnumbered sellers: 6 funds opened new BLTE positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Atria Wealth Solutions, opening a new position worth an estimated $927K.
- 6 institutional investors held Belite Bio (BLTE) as of Q2 2022, up from 0 in Q1 2022.
- Funds reported $2.15M of Belite Bio stock for Q2 2022.
- 6 funds opened new Belite Bio positions in Q2 2022 and 0 closed out, a net change of +6 holders.
- The largest Belite Bio buyer in Q2 2022 was Atria Wealth Solutions, an estimated $927K added.
Based on aggregated 13F filings for Q2 2022.